Almost 60% (13 out of 22) of patients with advanced breast cancer had delayed disease progression when bispecific antibodies for HER2 and CD3 were combined with IL-2 and granulocyte monocyte colony stimulating factor (GM-CSF) in a Phase I clinical trial [114]. This evidence concerns the gene IL2 and breast cancer.